Precigen registers Phase 3 study of zopapogene imadenovec in pediatric RRP
The study, led by Precigen, Inc., plans to enroll 15 participants and has a planned start date of December 31, 2026, with a planned primary completion date of January 2029. It plans to assess the safety and efficacy of zopapogene imadenovec, an investigational immunotherapy, in children with recurrent respiratory papillomatosis.
Primary source
ClinicalTrials.gov registry record, October 28, 2026
Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children
Read the source: Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation